This randomized, open-label, crossover study will evaluate the relative bioavailability of
ritonavir-boosted danoprevir fixed dose combination tablets (FDC) as compared to ad hoc
combination of reference tablets of danoprevir and ritonavir in healthy volunteers. Subjects
will be randomized to 1 of 6 treatment sequences to receive single oral doses of either an
FDC of danoprevir and ritonavir or danoprevir and ritonavir as separate tablets. In a
crossover design, subjects will participate in 3 study periods with at least a 7-day washout
between periods. In Part 2, single dose administration of film-coated FDCs will be compared
to reference tablets.